杨森生物品牌怎么样 申请店铺

我要投票 杨森生物在医疗器械行业中的票数:272 更新时间:2025-06-08
杨森生物是哪个国家的品牌?「杨森生物」是 武汉杨森生物技术有限公司 旗下著名品牌。该品牌发源于湖北省武汉市,由创始人靳苗在2009-04-28期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力杨森生物品牌出海!将品牌入驻外推网,定制杨森生物品牌推广信息,可以显著提高杨森生物产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

杨森生物怎么样

武汉杨森生物技术有限公司是一家从事医疗器械研发和代理的企业,成立于2009年4月,公司位于湖北省武汉国家生物产业基地。企业始终坚持以自主创新为主,企业结构和规模得到迅速的发展和壮大。  

公司从2009年50万的注册资金,到现在已有注册资产779.22万;拥有1000m2GMP认证的生产厂房,200m2 办公楼;目前已拥有3项发明专利和1项实用新型,3项发明专利和1项PCT专利已受理,公司设置3个职能部门,包括研发部门、管理部门和销售部门;现有员工30余人,其中博士硕士以上学历者占总人数的83%,体现企业自主研发特色。

杨森公司所研制的三层仿生小口径人造血管项目是以人体自身的小动脉的结构作为参照的人造血管。与以前普遍采用纯纤维材料(涤纶织物或蚕丝)或某种高分子材料(ePTFE)单一组成的人造血管相比,本项目创造性地设计出具有三层结构的更接近于人体血管结构和功能的复合人造血管。该人造血管不仅模拟人体小动脉血管的三层解剖结构(单层上皮细胞构成的血管内膜、富含弹力的平滑肌纤维构成的中层和结缔组织构成的外层),而且还模拟每层结构的功能,内层采用聚氨酯与非水溶性丝素粉体相结合模拟内皮及其少量结缔组织,中间层采用纺织材料制成的管状弹性织物来模拟人体血管中的富含弹性的平滑肌纤维层,外层采用聚氨酯与非水溶性丝素粉体来模拟结缔组织;同时沿厚度方向由内向外实现梯度多孔,模拟血管壁的微孔结构。  

核心发明专利:一种织物增强的复合人造血管,专利号:200610166568。 该项目已于2014年完成该项目的生产许可认证,2014年底将样品递交至第三方机构进行形式审核,预计2015年完成该第三方检测工作并提交至国家药监局进行临床申报工作,2016年-2018年完成该项目的临床试验,2018年中旬获取该项目的注册批件并在国内进行上市销售。在此期间,力争同时完成欧盟的CE认证与通过FDA510K证书,从而打开产品的国际市场。  

公司的人造血管项目已获得专利,目前该人造血管在动物实验中已取得重大突破,正处于投产阶段,这将是较符合人体生理结构的人造血管。一旦产品成功上市,将推动该领域民族工业的发展,对中国生物医用材料的发展也具有重要的经济价值和社会价值。


Wuhan YANGSEN Biotechnology Co., Ltd. is an enterprise engaged in R & D and agency of medical devices, established in April 2009, located in Wuhan National biological industry base, Hubei Province. Enterprises always adhere to the principle of independent innovation, and their structure and scale have been rapidly developed and expanded. The company has registered capital of RMB 500000 in 2009, and now has registered assets of RMB 7792200; it has 1000m2gmp certified production plant and 200m2 office building; at present, it has 3 invention patents and 1 utility model, 3 invention patents and 1 PCT patent have been accepted, and the company has set up 3 functional departments, including R & D department, management department and sales department; it has more than 30 employees, including Bo Bo Scholars with master's degree or above account for 83% of the total number, reflecting the independent R & D characteristics of the enterprise. The three-layer bionic small caliber artificial blood vessel project developed by Janssen company is an artificial blood vessel with reference to the structure of human own small artery. Compared with the artificial blood vessel made of pure fiber material (polyester fabric or silk) or a kind of polymer material (ePTFE), this project creatively designs a composite artificial blood vessel with three-layer structure, which is closer to the structure and function of human blood vessel. The vascular prosthesis not only simulates the three-layer anatomical structure of human arterioles (the vascular intima composed of monolayer epithelial cells, the middle layer composed of elastic smooth muscle fibers and the outer layer composed of connective tissue), but also simulates the function of each layer structure. The inner layer uses polyurethane combined with insoluble silk powder to simulate the endothelium and a small amount of connective tissue, and the middle layer uses spinning The tubular elastic fabric is made of the fabric material to simulate the elastic smooth muscle fiber layer in human blood vessels, and the outer layer is polyurethane and insoluble silk fibroin powder to simulate the connective tissue; at the same time, the gradient porous is realized from the inside to the outside along the thickness direction to simulate the microporous structure of the blood vessel wall. Core invention patent: a fabric reinforced composite artificial blood vessel, patent No.: 200610166568. The project has completed the production license certification of the project in 2014. At the end of 2014, the samples will be submitted to a third-party organization for formal review. It is expected that the third-party testing will be completed in 2015 and submitted to the State Food and Drug Administration for clinical application. The clinical trials of the project will be completed in 2016-2018. In the middle of 2018, the project's registration approval will be obtained and listed in China. During this period, strive to complete the CE certification of EU and pass the fda510k certificate at the same time, so as to open the international market of products. The company's artificial blood vessel project has been patented. At present, the artificial blood vessel has made a major breakthrough in animal experiments and is in the production stage, which will be more in line with human physiological structure. Once the product is successfully listed, it will promote the development of national industry in this field, and also has important economic and social value for the development of biomedical materials in China.

本文链接: https://brand.waitui.com/6bfa48b93.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

洪灏辞任华福国际CEO

记者获悉,知名策略师洪灏日前已辞任华福国际(香港)金融控股有限公司CEO一职,目前担任其本人公司Lotus Asset Management的管理合伙人兼首席投资官。华福国际在回应记者采访时表示,公司尊重洪灏基于个人职业规划作出的决定,今后将与洪灏在相关业务领域继续保持合作。目前华福国际各项业务进展顺利,核心团队稳定,未来将持续推进国际化战略。(每经网)

2小时前

国产具身大模型首次获得汽车制造全场景验证

6月7日,东风柳州汽车有限公司与智平方(深圳)科技有限公司在深圳正式签署战略合作协议,双方将共同探索具身大模型在汽车制造全方位场景的首次深度应用。根据协议,搭载智平方全域全身VLA(GOVLA)大模型的通用智能机器人AlphaBot 2(爱宝)将首次进驻东风柳汽汽车工厂,在上下料、拖拽料车、贴挡风玻璃标签、收纳保护布等多个场景执行智能化作业。这标志着国产具身大模型首次获得汽车制造全场景验证。(新浪财经)

2小时前

微软将对人工智能模型的“安全性”进行排名

微软将对人工智能模型的“安全性”进行排名。(新浪财经)

2小时前

鸿蒙电脑构建了从芯片到系统的自主体系

赛迪智库信息化与软件产业研究所信息技术研究室副主任王洁琼分析,鸿蒙PC(个人电脑)构建了从芯片到系统的自主体系,一定程度上打破了Windows、macOS等国外产品的长期商业垄断,有望实现国产操作系统在个人电脑消费市场的规模化商用。目前,鸿蒙操作系统的主要市场是在手机、平板、汽车等移动终端,推出鸿蒙PC将延续其移动端的用户优势及产品能力,对PC端大众消费市场格局有较大影响。(经济日报)

2小时前

Meta 首席技术官:今年是增强与虚拟现实业务的“关键之年”

Meta 首席技术官 Andrew “Boz” Bosworth 近期在接受采访时表示,2025 年可能是 Meta 旗下现实实验室(Reality Labs)的“伟大之年(the year of greatness)”,也可能是元宇宙沦为“传奇失败案例”的一年。而如今,Bosworth 看起来更倾向于相信其有实现伟大的潜力,但最终的决定权仍在市场手中。(IT之家)

2小时前

本页详细列出关于杨森生物的品牌信息,含品牌所属公司介绍,杨森生物所处行业的品牌地位及优势。
咨询